9 completed, 1 terminated. 10 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Completed 9, Terminated 1 |
Follow Acellular Pertussis: new trials by email Literature Review of Acellular Pertussis trials Research Report on Acellular Pertussis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Immunogenicity of a Booster Dose of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744) Infanrix hexa, Prevenar 13, GSK217744 - Acellular Pertussis, Hepatitis B | Phase 2 | Completed | GlaxoSmithKline | 657 | 2011-10-14 | 2020-07-17 |
| Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744) Infanrix hexa™, Prevenar 13®, GSK217744 - Tetanus, Poliomyelitis | Phase 2 | Completed | GlaxoSmithKline | 721 | 2010-12-09 | 2018-08-20 |
| Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster Dose GSK2202083A vaccine, Infanrix hexa™, Menjugate™ - Tetanus, Diphtheria | Phase 2 | Completed | GlaxoSmithKline | 391 | 2010-08-18 | 2020-01-21 |
| Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants GSK2202083A vaccine, Prevenar 13®, Infanrix hexa™ - Tetanus, Hepatitis B | Phase 2 | Completed | GlaxoSmithKline | 480 | 2010-05-17 | 2018-08-20 |
| Immunogenicity and Safety Study of GSK Biologicals' GSK2202083A Vaccine in Healthy Infants at 2, 3 and 4 Months of Age GSK2202083A vaccine, 10-valent pneumococcal vaccine (GSK 1024850A), Infanrix hexa™ - Tetanus, Diphtheria | Phase 2 | Completed | GlaxoSmithKline | 421 | 2009-08-13 | 2020-01-03 |
| Feasibility Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants at 3, 5 and 11 Months of Age. GSK2202083A vaccine, Infanrix hexa, Menjugate - Tetanus, Poliomyelitis | Phase 2 | Terminated | GlaxoSmithKline | 16 | 2009-04-01 | 2018-06-06 |
| Immunogenicity and Reactogenicity of a Booster Dose of GSK Bio's DTPa-HBV-IPV/Hib Vaccine Infanrix Hexa - Acellular Pertussis, Diphtheria | Phase 2 | Completed | GlaxoSmithKline | 403 | 2008-02-01 | 2018-06-06 |
| Immunogenicity and Safety of a DTPa-HBV-IPV/Hib Vaccine Given at 2, 3 and 4 Months of Age Infanrix hexa Vaccine - Acellular Pertussis, Tetanus | Phase 2 | Completed | GlaxoSmithKline | 450 | 2006-10-01 | 2016-11-04 |
| Multicentre Booster & Immune Memory Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine or a Single Dose of 23-valent Plain Polysaccharide Vaccine in Healthy Children Aged 11-18 Mths, Previously Vaccinated in Study 103488 Pneumococcal (vaccine) - Acellular Pertussis, Tetanus | Phase 2 | Completed | GlaxoSmithKline | 689 | 2005-11-01 | 2016-09-23 |
| Comparison of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP and IPV Separately Administered Vaccines in Terms of Immune Response and Safety Prophylaxis: Diphtheria, tetanus, pertussis, poliovirus type 1, type 2 and type 3 - Diphtheria, Acellular Pertussis | Phase 2 | Completed | GlaxoSmithKline | 401 | 2002-11-01 | 2016-09-15 |
Diphtheria (10) · Tetanus (10) · Haemophilus Infections (9) · Hepatitis B (9) · Poliomyelitis (9)
Actinomycetales Infections (10) · Bacterial Infections (10) · Bacterial Infections and Mycoses (10) · Clostridium Infections (10) · Corynebacterium Infections (10) · Gram-Positive Bacterial Infections (10) · Infections (10) · Blood-Borne Infections (9) · Central Nervous System Diseases (9) · Central Nervous System Infections (9) · Communicable Diseases (9) · DNA Virus Infections (9) · Digestive System Diseases (9) · Enterovirus Infections (9) · Gram-Negative Bacterial Infections (9)
diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine (8) · 13-valent pneumococcal vaccine (3) · 10-valent pneumococcal vaccine (1) · PHiD-CV vaccine (1) · Pneumococcal Vaccines (1) · RIX4414 vaccine (1) · Tetanus Toxoid (1)
GlaxoSmithKline (10)
Finland (4) · Dominican Republic (2) · Germany (2) · Poland (2) · Canada (1) · France (1) · Slovakia (1) · United States (1)
2009 (1)